TEL AVIV, Israel, March 7, 2013 /PRNewswire/ -- InspireMD, Inc. (OTC: NSPR) (the "Company" or "InspireMD") filed an amended registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to the resumption of a proposed underwritten public offering. Under the amended registration statement, the Company is offering $30 million worth of its shares of common stock. In addition, InspireMD intends to grant the underwriters a 30-day option to purchase up to an aggregate of 15 percent additional shares of common stock to cover over-allotments, if any. The Company intends to use the proceeds from the offering to support the worldwide commercialization of the MGuard™ Coronary in acute myocardial infarction, pursue FDA approval in the U.S., to redeem its convertible debentures, and for general corporate purposes. As part of the offering, the Company has applied to list its shares of common stock on the NYSE MKT. A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. Cowen and Company, LLC is sole book runner and JMP Securities is acting as co-lead manager. This offering shall be made only by means of a prospectus. Once available, a prospectus relating to these securities may be obtained from Cowen and Company, LLC (c/o Broadridge Financial Services) at 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, or by calling +1(631)274-2806. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.